On Demand 2021 Saturday General Sessions

This collection covers general sessions from Saturday's program. This includes plenaries, and symposia. The sessions listed below are included in this package:

  • Presidential Plenary: Innovate, Diversify and Expand Allergy/Immunology Practice
  • Addressing Mental Health Challenges in Patients with Asthma and Allergic Diseases
  • Combatting Misinformation in Medicine
  • Don’t Sleep on Sleep – Why Sleep Disorders are Important to the Allergist
  • Drug Hypersensitivity Reactions in 2021: What Should We Know
  • Management of Nasal Polyps: When Are Surgery And Biologic Agents Required?
  • 7 for 11, Update on Pediatric Allergy & immunology - Cosponsored with AAP-Section of Allergy & Immunology
  • Editor’s Pick – Best Articles from Annals of Allergy, Asthma and Immunology
  • Emerging Concepts in Environmental Immunotherapy
  • Coding and Government Relations
  • Disparities in the Air We Breathe
  • Practical Management of AERD
  • Role of Genetic Testing in Diagnosis and Management of Immunodeficiency

Accreditation
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 19.25 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Target Audience

Medical professionals who treat patients with allergic and/or immunological conditions:

  • Practicing allergist/immunologists
  • Allergy/immunology Fellows-in-Training
  • Physician assistants
  • Nurses and advanced practice nurses
  • Allied health professionals
  • Primary care physicians
  • Other medical professionals

Learning Objectives

Upon completion of this session, participants should be able to:

  • Educate allergy/immunology specialists about the adverse outcomes experienced by patients with depression and anxiety in asthma, food allergy, and other allergic disorders
  • Describe effective diagnostic tools that assist the clinician in improving health outcomes is patients burdened with depression/anxiety disorders
  • Describe various interventions by allergy/immunology specialists partnering with primary care, psychology, and/or psychiatrists in controlling mental health diseases resulting in a better quality of life and lower health costs
  • Review the effects of sleep on the immune system
  • Review clinical management of pediatric sleep disorders, with emphasis on OSA and how allergies may contribute
  • Review clinical management of adult OSA and how allergies and asthma may be associated
  • Classify different cutaneous manifestations of drug hypersensitivity including urticaria/angioedema, SJS/TEN, AGEP, DRESS, maculopapular exanthem
  • Discuss how to diagnose and manage hypersensitivity to beta-lactams and NSAIDs
  • Describe risk stratification for drug allergy, adverse reactions to biologics and drug-induced anaphylaxis
  • Review the underlying endotypes and phenotypes of nasal polyps
  • Describe the potential benefits and risks of medical management of nasal polyps
  • Understand the potential benefits and risks of surgical management of nasal polyps
  • Review new diagnosis and treatments for food allergy
  • Understand updates in pediatric asthma and allergy
  • Review change sin diagnosis and management of pediatric skin and immune disorders
  • Incorporate current knowledge towards food allergy diagnosis and management
  • Use phenotyping and biomarkers to select the most appropriate biologics for treatment of asthma
  • Implement shared decision making into clinical practice for patients with various allergic conditions
  • Describe strategies to make administration of SCIT safer and more acceptable given practice restrictions imposed due to the COVID19 pandemic
  • Discuss advantages SLIT could offer to your practice and your patients given patient concerns about in-person visits and practice restrictions imposed due to the COVID19 pandemic
  • Describe practical ways in which to easily ramp up SLIT and/or SCIT delivery to your practice during the pandemic
  • Describe coding changes and updates relevant to allergy practice
  • Describe how allergists and organizations have been involved using past examples and calls to action for future work
  • Understand a governmental and legislative update for the allergist
  • Identify major advances in key areas of genetic testing research in newly diagnosed genetic disorders
  • Demonstrate knowledge of basic processes linking molecular and cellular biology and genetics with clinical manifestations of immunodeficiency
  • Translate emerging clinical science principles to clinical practice with immune deficiency disorders
Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months. The ACCME defines a “ineligible company” as companies whose primary business is producing, marketing, selling, re-selling, or distributing health care goods or services, used by or on patients. Examples of such organizations include: 
 
•    Advertising, marketing, or communication firms whose clients are ineligible companies
•    Bio-medical startups that have begun a governmental regulatory approval process
•    Compounding pharmacies that manufacture proprietary compounds
•    Device manufacturers or distributors
•    Diagnostic labs that sell proprietary products
•    Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
•    Manufacturers of health-related wearable products
•    Pharmaceutical companies or distributors
•    Pharmacy benefit managers
•    Reagent manufacturers or sellers
  
The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.
Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.
Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All identified relevant financial relationships have been mitigated.

Course summary
Available credit: 
  • 19.25 AMA PRA Category 1 Credit™
  • 19.25 Attendance
Course opens: 
11/19/2021
Course expires: 
11/18/2024
Part of: 
On Demand ACAAI 2021 Annual Scientific Meeting General Sessions
Rating: 
0

William C. Anderson, MD, FACAAI

Susan R. Bailey, MD, FACAAI

Aleena Banerji, MD

Aaron Bernstein, MD, MPH

David I. Bernstein, MD, FACAAI

Theresa A. Bingemann, MD, FACAAI

J. Andrew Bird, MD, FACAAI

Sherwood Brown, MD, PhD

Warner W. Carr, MD, FACAAI

Nicole M. Chase, MD, FACAAI

Seong Cho, MD, FACAAI 

Timothy J. Craig, DO, FACAAI

Peter S. Creticos, MD

Charlotte Cunningham-Rundles, MD, PhD

Carla M. Davis, MD, FACAAI

Anne K. Ellis, MD, MSc, FACAAI

Mary Beth Fasano, MD, MSPH, FACAAI

Bill Finerfrock

Luz S. Fonacier, MD, FACAAI

Mitchell H. Grayson, MD, FACAAI

Lara M. Gross, MD

Jessica Gold, MD, MS

Payel Gupta, MD, FACAAI

Ruchi Gupta, MD, MPH

John B. Hagan, MD, FACAAI

Bridgette L.  Jones, MD

Jeremy S. Katcher, MD, FACAAI

Brian T. Kelly, MD, MA, FACAAI

David A. Khan, MD, FACAAI

Fatima S. Khan, MD, FACAAI

Samantha M. Knox, MD

Merin E. Kuruvilla, MD, FACAAI

Tanya M. Laidlaw, MD

Gerald B. Lee, MD, FACAAI

Joshua Levy, MD, MPH

Jay A. Lieberman, MD, FACAAI

Sandra Y. Lin, MD

Todd A. Mahr, MD, FACAAI

Bryan L. Martin, DO, FACAAI

Gailen D. Marshall, Jr., MD, PhD, FACAAI

Kathleen May, MD, FACAAI

Syed Shazad Mustafa, MD, FACAAI 

David A. Peden, MD, FACAAI

John J. Oppenheimer, MD, FACAAI

Jordan S Orange, MD, PhD, FACAAI

Elizabeth J. Phillips, MD

Brian D. Robertson, MD, FACAAI

Jane Robinson, PhD

Sergio D. Rosenzweig, MD, PhD

Sarah W. Spriet, DO, FACAAI

Whitney Stevens, MD, PhD

David R. Stukus, MD, FACAAI

J. Wesley Sublett, MD, MPH, FACAAI

James L. Sublett, MD, FACAAI

Jonathan S. Tam, MD, FACAAI

Mike Tankersley, MD, MBA, FACAAI

James M. Tracy, DO, FACAAI

Dana V. Wallace, MD, FACAAI

Julie Wang, MD, FACAAI

Andrew A. White, MD, FACAAI

The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Available Credit

  • 19.25 AMA PRA Category 1 Credit™
  • 19.25 Attendance
Please login or create an account to take this course.